AAA today announced that it has entered into an exclusive worldwide license agreement with Cancer Targeted Technology, LLC (CTT) to develop and market an investigational new drug product, F-18-labeled CTT1057. CTT1057 is a ligand of Prostate-Specific Membrane Antigen (PSMA) for Positron Emission Tomography (PET) imaging of prostate cancer. CTT has developed a phosphoramidate-based peptide, which specifically binds to PSMA. A Phase I study in 20 patients was conducted at the University of California, San Francisco. AAA will work to further develop and commercialize this diagnostic agent for prostate cancer. The terms of the agreement include an upfront licensing fee, as well as certain milestone and royalty payments.

A worldwide presence

AAA operates in Belgium, Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, UK and USA while its distribution network covers more than 30 countries. Please point to any of the locations to pull up specific details about each facility.

Pipeline

We are developing a pipeline of theragnostic pairings for oncology indications. AAA’s theragnostic platform involves radiolabeling a targeting molecule with either gallium Ga 68 for diagnostic use, or lutetium Lu 177 for therapy.

Molecular Nuclear Medicine

Making personalised treatment a reality.

AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) and SPECT (Single Photon Emission Tomography) radiopharmaceuticals and is able to produce and deliver both commercial drugs and research products.

Discover

Our documentary about Molecular Nuclear Medicine and cancer.

Molecular Nuclear Medicine with a 22’ documentary from the history of radioactivity and cancer to the most modern Theragnostic techniques. You will understand how SPECT and PET work, and how Radio Metabolic Therapy can treat cancer.

This website uses cookies to improve the user experience of the site. By using the site, you agree to accept our use of cookies. If you require further information or do not wish to accept our use of cookies, visit our Website Privacy Policy page×